Interchange Capital Partners LLC Sells 4,200 Shares of Johnson & Johnson $JNJ

Interchange Capital Partners LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 88.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 548 shares of the company’s stock after selling 4,200 shares during the period. Interchange Capital Partners LLC’s holdings in Johnson & Johnson were worth $84,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of JNJ. Brighton Jones LLC raised its stake in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new position in Johnson & Johnson during the first quarter worth $218,000. GAMMA Investing LLC raised its stake in Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after buying an additional 14,118 shares during the last quarter. Kiley Juergens Wealth Management LLC raised its stake in Johnson & Johnson by 2.5% during the first quarter. Kiley Juergens Wealth Management LLC now owns 17,909 shares of the company’s stock worth $2,970,000 after buying an additional 435 shares during the last quarter. Finally, Community Bank N.A. raised its stake in Johnson & Johnson by 4.0% during the first quarter. Community Bank N.A. now owns 47,656 shares of the company’s stock worth $7,903,000 after buying an additional 1,835 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. HSBC lifted their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday. Citigroup raised their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Finally, Argus set a $210.00 price target on shares of Johnson & Johnson in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Stock Up 0.6%

Shares of NYSE JNJ opened at $193.27 on Friday. The stock has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a P/E/G ratio of 2.26 and a beta of 0.40. The company has a 50-day moving average price of $180.49 and a 200-day moving average price of $164.80. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion for the quarter. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.